問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Search Result

Search Result

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

China Medical University Hospital

Recruiting

List

785Cases

2022-06-30 - 2024-03-12

Phase III

Completed

  • Condition/Disease

  • Test Drug

Participate Sites
4Sites

Recruiting4Sites

2024-12-01 - 2028-08-18

Phase II

Active
VELOCITY-HNSCC Substudy-01: A Phase 2 Study of Novel Combination Therapies in Participants With Previously Untreated Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma Regardless of PD-L1 Expression Status

  • Condition/Disease

    Head and Neck Squamous Cell Carcinoma

  • Test Drug

    Zimberelimab Domvanalimab

Participate Sites
6Sites

Recruiting6Sites

2024-04-12 - 2028-12-31

Phase II

Active
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Multicenter, Dose-Ranging Study Evaluating the Efficacy and Safety of GS-1427 in Adult Participants With Moderately to Severely Active Ulcerative Colitis (UC)

  • Condition/Disease

    Moderately to Severely Active Ulcerative Colitis

  • Test Drug

    GS-1427

Participate Sites
8Sites

Recruiting8Sites

2022-10-31 - 2026-12-31

Phase III

Active

  • Condition/Disease

  • Test Drug

Participate Sites
4Sites

Recruiting4Sites

2023-06-01 - 2025-12-31

Phase III

Active

  • Condition/Disease

  • Test Drug

Participate Sites
5Sites

Recruiting5Sites

2024-12-01 - 2028-12-31

Phase I/II

Active

  • Condition/Disease

  • Test Drug

Participate Sites
5Sites

Recruiting5Sites

2020-11-30 - 2025-12-31

Phase III

Completed

  • Condition/Disease

  • Test Drug

Participate Sites
3Sites

Recruiting3Sites

2025-03-31 - 2028-01-31

Phase I

Active
A Phase 1B, Multicenter, Open-Label Study of the Safety and Efficacy of CHS-114 in Combination With Toripalimab With or Without Other Treatments in Participants With Advanced or Metastatic Solid Tumors

  • Condition/Disease

    Metastatic Solid Tumor、 Advanced Solid Tumor

  • Test Drug

    靜脈點滴注射劑 靜脈點滴注射劑

Participate Sites
10Sites

Recruiting10Sites

2024-06-28 - 2028-03-31

Phase III

Active
A Phase 3 Open-label, Randomized Controlled Study to Evaluate the Efficacy and Safety of Petosemtamab Compared With Investigator's Choice Monotherapy Treatment in Previously Treated Patients With Incurable, Metastatic/Recurrent Head and Neck Squamous Cell Carcinoma

  • Condition/Disease

    Head and Neck Squamous Cell Carcinoma

  • Test Drug

    Intravenous infusion

Participate Sites
8Sites

Recruiting8Sites

2024-06-28 - 2028-05-31

Phase III

Active
A phase 3 randomized, open-label study to evaluate the efficacy and safety of petosemtamab plus pembrolizumab vs pembrolizumab in first-line treatment of recurrent or metastatic PD-L1+ head and neck squamous cell carcinoma

  • Condition/Disease

    Head and Neck Squamous Cell Carcinoma

  • Test Drug

    petosemtamab

Participate Sites
7Sites

Recruiting7Sites

1 23 24 25 26 27 79
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB